Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical Research

Is prostate cancer stage migration continuing for black men in the PSA era?

Prostate Cancer and Prostatic Diseases volume 20, pages 210–215 (2017)Cite this article

Subjects

Abstract

Background:

In the United States, disease-specific mortality from prostate cancer (PC) is highest among black men. While the introduction of widespread PSA testing has been associated with a downward stage migration, whether this trend continues in the late PSA era and for black men is unknown. The objective of our study was to evaluate current PC stage migration patterns in the United States by race.

Methods:

The Surveillance, Epidemiology and End Results (SEER) registry was queried to obtain all cases of PC reported between 2000 and 2013. Year of diagnosis was categorized into 2000–2003, 2004–2007, 2008–2010 and 2011–2013. Predictors of distant stage PC at diagnosis were determined using logistic regression adjusted for year of diagnosis, age at diagnosis, SEER region and race.

Results:

A total of 791 184 PC cases were identified. The cohort comprised 78.9% (n=594 920) white and 14.1% (n=106 133) black men. The stage at diagnosis was 83.3% localized, 12.0% regional and 4.7% distant. Age-adjusted incidence demonstrated a steady decline for black men in all time groups while white men had a stable incidence of distant disease between 2000 and 2013. In univariate analysis, black men in the 2004–2007 (OR 0.86 (0.81–0.93)) and 2008–2010 cohorts (OR 0.85 (0.79–0.91)) were less likely to be diagnosed with metastatic PC as compared with the 2000–2003 baseline cohort. In multivariate analysis, the 2004–2007 black cohort was less likely to be diagnosed with distant PC (OR 0.90 (0.84–0.97)). This trend was not observed in white men who in multivariate analysis had an increased risk of distant PC in the 2004–2007 (OR 1.08 (1.04–1.11)), 2008–2010 (OR 1.22 (1.18–1.27)) and 2011–2013 (OR 1.65 (1.59–1.71)) groups.

Conclusions:

PC downward stage migration continues in black men but not in white men. Discontinuation of PSA-based screening for PC could disproportionately affect black men.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1a
Figure 1b

Similar content being viewed by others

References

  1. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E . Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987; 317: 909–916.

    Article  CAS  PubMed  Google Scholar 

  2. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324: 1156–1161.

    Article  CAS  PubMed  Google Scholar 

  3. Potosky AL, Miller BA, Albertsen PC, Kramer BS . The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995; 273: 548–552.

    Article  CAS  PubMed  Google Scholar 

  4. Amling CL, Blute ML, Lerner SE, Bergstralh EJ, Bostwick DG, Zincke H . Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc 1998; 73: 401–406.

    Article  CAS  PubMed  Google Scholar 

  5. Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC . Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001; 166: 416–419.

    Article  CAS  PubMed  Google Scholar 

  6. Noldus J, Graefen M, Haese A, Henke RP, Hammerer P, Huland H . Stage migration in clinically localized prostate cancer. Eur Urol 2000; 38: 74–78.

    Article  CAS  PubMed  Google Scholar 

  7. Moul JW, Wu H, Sun L, McLeod DG, Amling C, Lance R et al. Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. Surgery 2002; 132: 213–219.

    Article  PubMed  Google Scholar 

  8. Scosyrev E, Wu G, Mohile S, Messing EM . Prostate-specific antigen screening for prostate cancer and the risk of overt metastatic disease at presentation: analysis of trends over time. Cancer 2012; 118: 5768–5776.

    Article  PubMed  Google Scholar 

  9. Etzioni R, Gulati R, Falcon S, Penson DF . Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making 2008; 28: 323–331.

    Article  PubMed  Google Scholar 

  10. Aus G, Bergdahl S, Lodding P, Lilja H, Hugosson J . Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer—results from a prospective, population-based randomized controlled trial. Eur Urol 2007; 51: 659–664.

    Article  PubMed  Google Scholar 

  11. Andriole GL, Crawford ED, Grubb RL III, Buys SS, Chia D, Church TR et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310–1319.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320–1328.

    Article  PubMed  Google Scholar 

  13. Moyer VA U.S. Preventive Services Task Force.. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157: 120–134.

    Article  PubMed  Google Scholar 

  14. Jani AB, Vaida F, Hanks G, Asbell S, Sartor O, Moul JW et al. Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. Int J Cancer 2001; 96: 363–371.

    Article  CAS  PubMed  Google Scholar 

  15. Morton RA Jr . Racial differences in adenocarcinoma of the prostate in North American men. Urology 1994; 44: 637–645.

    Article  PubMed  Google Scholar 

  16. King H, Diamond E, Lilieneld AM . Some epidemiological aspects of cancer of the prostate. J Chronic Dis 1963; 16: 117–153.

    Article  CAS  PubMed  Google Scholar 

  17. Powell IJ, Bock CH, Ruterbusch JJ, Sakr W . Evidence supports a faster growth rate and/or earlier transformation to clinically significant prostate cancer in black than in white American men, and influences racial progression and mortality disparity. J Urol 2010; 183: 1792–1796.

    Article  PubMed  Google Scholar 

  18. Hoffman RM, Gilliland FD, Eley JW, Harlan LC, Stephenson RA, Stanford JL et al. Racial and ethnic differences in advanced-stage prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2001; 93: 388–395.

    Article  CAS  PubMed  Google Scholar 

  19. Thompson I, Tangen C, Tolcher A, Crawford E, Eisenberger M, Moinpour C . Association of African-American ethnic background with survival in men with metastatic prostate cancer. J Natl Cancer Inst 2001; 93: 219–225.

    Article  CAS  PubMed  Google Scholar 

  20. Farkas A, Schneider D, Perrotti M, Cummings KB, Ward WS . National trends in the epidemiology of prostate cancer, 1973 to 1994: evidence for the effectiveness of prostate-specific antigen screening. Urology 1998; 52: 444–448; discussion 448-449.

    Article  CAS  PubMed  Google Scholar 

  21. Eifler JB, Feng Z, Lin BM, Partin MT, Humphreys EB, Han M et al. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int 2013; 111: 22–29.

    Article  PubMed  Google Scholar 

  22. Welch HG, Gorski DH, Albertsen PC . Trends in metastatic breast and prostate cancer—lessons in cancer dynamics. N Engl J Med 2015; 373: 1685–1687.

    Article  PubMed  Google Scholar 

  23. Powell IJ, Vigneau FD, Bock CH, Ruterbusch J, Heilbrun LK . Reducing prostate cancer racial disparity: evidence for aggressive early prostate cancer PSA testing of African American men. Cancer Epidemiol Biomarkers Prev 2014; 23: 1505–1511.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM . Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis 2016; 19: 395–397.

    Article  CAS  PubMed  Google Scholar 

  25. Drazer MW, Huo D, Eggener SE . National prostate cancer screening rates after the 2012 US Preventive Services Task Force Recommendation discouraging prostate-specific antigen-based screening. J Clin Oncol 2015; 33: 2416–2423.

    Article  PubMed  Google Scholar 

  26. Demark-Wahnefried W, Catoe KE, Paskett E, Robertson CN, Rimer BK . Characteristics of men reporting for prostate cancer screening. Urology 1993; 42: 269–274; discussion 274–265.

    Article  CAS  PubMed  Google Scholar 

  27. Demark-Wahnefried W, Strigo T, Catoe K, Conaway M, Brunetti M, Rimer BK et al. Knowledge, beliefs, and prior screening behavior among blacks and whites reporting for prostate cancer screening. Urology 1995; 46: 346–351.

    Article  CAS  PubMed  Google Scholar 

  28. Smith RA, Andrews K, Brooks D, DeSantis CE, Fedewa SA, Lortet-Tieulent J et al. Cancer screening in the United States, 2016: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2016; 66: 96–114.

    Article  PubMed  Google Scholar 

  29. Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL et al. Early detection of prostate cancer: AUA Guideline. J Urol 2013; 190: 419–426.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P Clinical Guidelines Committee of the American College of, P. Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 2013; 158: 761–769.

    Article  PubMed  Google Scholar 

  31. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ et al. American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 2010; 60: 70–98.

    Article  PubMed  Google Scholar 

  32. Izawa JI, Klotz L, Siemens DR, Kassouf W, So A, Jordan J et al. Prostate cancer screening: Canadian guidelines 2011. Can Urol Assoc J 2011; 5: 235–240.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Hayes JH, Barry MJ . Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. JAMA 2014; 311: 1143–1149.

    Article  CAS  PubMed  Google Scholar 

  34. Cooperberg MR, Carroll PR . Trends in management for patients with localized prostate cancer, 1990-2013. JAMA 2015; 314: 80–82.

    Article  CAS  PubMed  Google Scholar 

  35. Stallings FL, Ford ME, Simpson NK, Fouad M, Jernigan JC, Trauth JM et al. Black participation in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000; 21 (Suppl): 379S–389S.

    Article  CAS  PubMed  Google Scholar 

  36. Barocas DA, Grubb R III, Black A, Penson DF, Fowke JH, Andriole G et al. Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer 2013; 119: 2223–2229.

    Article  PubMed  Google Scholar 

  37. Pettaway CA, Troncoso P, Ramirez EI, Johnston DA, Steelhammer L, Babaian RJ . Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens. J Urol 1998; 160: 437–442.

    Article  CAS  PubMed  Google Scholar 

  38. Sundi D, Kryvenko ON, Carter HB, Ross AE, Epstein JI, Schaeffer EM . Pathological examination of radical prostatectomy specimens in men with very low risk disease at biopsy reveals distinct zonal distribution of cancer in black American men. J Urol 2014; 191: 60–67.

    Article  PubMed  Google Scholar 

  39. Minamimoto R, Uemura H, Sano F, Terao H, Nagashima Y, Yamanaka S et al. The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level. Ann Nucl Med 2011; 25: 21–27.

    Article  CAS  PubMed  Google Scholar 

  40. Lecouvet FE, El Mouedden J, Collette L, Coche E, Danse E, Jamar F et al. Can whole-body magnetic resonance imaging with diffusion-weighted imaging replace Tc 99m bone scanning and computed tomography for single-step detection of metastases in patients with high-risk prostate cancer? Eur Urol 2012; 62: 68–75.

    Article  PubMed  Google Scholar 

  41. Ross LE, Berkowitz Z, Ekwueme DU . Use of the prostate-specific antigen test among U.S. men: findings from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev 2008; 17: 636–644.

    Article  PubMed  Google Scholar 

  42. Bennett CL, Ferreira MR, Davis TC, Kaplan J, Weinberger M, Kuzel T et al. Relation between literacy, race, and stage of presentation among low-income patients with prostate cancer. J Clin Oncol 1998; 16: 3101–3104.

    Article  CAS  PubMed  Google Scholar 

  43. Hebert JR, Hurley TG, Olendzki BC, Teas J, Ma Y, Hampl JS . Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. J Natl Cancer Inst 1998; 90: 1637–1647.

    Article  CAS  PubMed  Google Scholar 

  44. Major JM, Norman Oliver M, Doubeni CA, Hollenbeck AR, Graubard BI, Sinha R . Socioeconomic status, healthcare density, and risk of prostate cancer among African American and Caucasian men in a large prospective study. Cancer Causes Control 2012; 23: 1185–1191.

    Article  PubMed  PubMed Central  Google Scholar 

  45. Hoffman RM, Harlan LC, Klabunde CN, Gilliland FD, Stephenson RA, Hunt WC et al. Racial differences in initial treatment for clinically localized prostate cancer. Results from the prostate cancer outcomes study. J Gen Intern Med 2003; 18: 845–853.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Whittemore AS, Wu AH, Kolonel LN, John EM, Gallagher RP, Howe GR et al. Family history and prostate cancer risk in black, white, and Asian men in the United States and Canada. Am J Epidemiol 1995; 141: 732–740.

    Article  CAS  PubMed  Google Scholar 

  47. Freedland SJ, Isaacs WB . Explaining racial differences in prostate cancer in the United States: sociology or biology? Prostate 2005; 62: 243–252.

    Article  PubMed  Google Scholar 

  48. Kutikov A, Cooperberg MR, Paciorek AT, Uzzo RG, Carroll PR, Boorjian SA . Evaluating prostate cancer mortality and competing risks of death in patients with localized prostate cancer using a comprehensive nomogram. Prostate Cancer Prostatic Dis 2012; 15: 374–379.

    Article  CAS  PubMed  Google Scholar 

  49. Siegel RL, Fedewa SA, Miller KD, Goding-Sauer A, Pinheiro PS, Martinez-Tyson D et al. Cancer statistics for Hispanics/Latinos, 2015. CA Cancer J Clin 2015; 65: 457–480.

    Article  PubMed  Google Scholar 

  50. Mersha TB, Abebe T . Self-reported race/ethnicity in the age of genomic research: its potential impact on understanding health disparities. Hum Genomics 2015; 9: 1.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, University of Illinois at Chicago, Chicago, IL, USA

    R W Dobbs, D T Greenwald, H Wadhwa & M R Abern

  2. School of Public Health, University of Illinois at Chicago, Chicago, IL, USA

    V L Freeman

Authors
  1. R W Dobbs
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D T Greenwald
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Wadhwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V L Freeman
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M R Abern
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M R Abern.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dobbs, R., Greenwald, D., Wadhwa, H. et al. Is prostate cancer stage migration continuing for black men in the PSA era?. Prostate Cancer Prostatic Dis 20, 210–215 (2017). https://doi.org/10.1038/pcan.2016.68

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2016.68

This article is cited by

Search

Advanced search

Quick links